Raltitrexed (Tomudex™) plus doxorubicin (DOX) in patients with advanced gastric cancer:: Interim results of a phase I dose escalation study

被引：0
|
作者：
Bjarnason, G [1 ]
Charpentier, D [1 ]
Winquist, E [1 ]
Wong, R [1 ]
Matthews, S [1 ]
Seymour, L [1 ]
机构：
[1] NCI, Canada Clin Trials Grp, Kingston, ON, Canada
来源：
ANNALS OF ONCOLOGY | 1998年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
459
引用
收藏
页码：120 / 120
页数：1
相关论文
共 50 条
  • [31] Phase I dose escalation study of pegylated liposomal doxorubicin (Caelyx®) in combination with topotecan in patients with advanced malignancies
    Hervé Ghesquières
    Sandrine Faivre
    Latifa Djafari
    Patricia Pautier
    Catherine Lhommé
    Stéphanie Lozahic
    Kamel Djazouli
    Jean-Pierre Armand
    Eric Raymond
    Investigational New Drugs, 2006, 24 : 413 - 421
  • [32] Raltitrexed combined with UFT: A phase I/II dose escalation study in metastatic colorectal cancer.
    Estevez, SV
    Vieitez, JM
    Garcia, AP
    de Castro, J
    Lorenzo, JRM
    Quintero, G
    Lacave, GJ
    de Paredes, MG
    Garcia-Vargas, JE
    ANNALS OF ONCOLOGY, 2000, 11 : 52 - 53
  • [33] Safety of intravenous application of a mistletoe extract - results from a phase I dose escalation study in patients with advanced cancer
    Huber, Roman
    Effertz, Carola
    Rieger, Sabine
    Troeger, Wilfried
    PHYTOMEDICINE, 2015, 22 : S16 - S16
  • [34] Safety of intravenously applied mistletoe extract - results from a phase I dose escalation study in patients with advanced cancer
    Huber, Roman
    Schlodder, Dietrich
    Effertz, Carola
    Rieger, Sabine
    Troeger, Wilfried
    BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2017, 17
  • [35] Safety of intravenously applied mistletoe extract – results from a phase I dose escalation study in patients with advanced cancer
    Roman Huber
    Dietrich Schlodder
    Carola Effertz
    Sabine Rieger
    Wilfried Tröger
    BMC Complementary and Alternative Medicine, 17
  • [36] Phase I dose-escalating study of raltitrexed ('Tomudex') and cisplatin in metastatic non-small cell lung cancer
    Manegold, C
    Buchholz, E
    Kloeppel, R
    Kreisel, C
    Smith, M
    LUNG CANCER, 2002, 36 (02) : 183 - 189
  • [37] Oxaliplatin plus raltitrexed in the treatment of patients with advanced colorectal cancer: A phase II study
    Martoni, A
    Mini, E
    Pinto, C
    Gentile, AL
    Nobili, S
    Dentico, P
    Marino, A
    Scicolone, S
    Angelelli, B
    Mazzei, T
    ANTICANCER RESEARCH, 2003, 23 (1B) : 687 - 691
  • [38] Phase I Dose Escalation Study of Gemcitabine plus Irinotecan in Advanced Solid Tumors
    Dugan, Elizabeth
    Truax, Roxanne
    Meadows, Kellen L.
    Blobe, Gerald C.
    Morse, Michael A.
    Fernando, Nishan H.
    Gockerman, Jon P.
    Petros, William P.
    Hurwitz, Herbert I.
    ANTICANCER RESEARCH, 2009, 29 (12) : 5149 - 5153
  • [39] Phase I dose escalation study of oxaliplatin combined with oral tegafur-uracil and leucovorin in patients with advanced gastric cancer
    Chen, JS
    Huang, JS
    Yang, TS
    Lin, YC
    Wang, HM
    Liau, CT
    Rau, KM
    ANTI-CANCER DRUGS, 2005, 16 (01) : 47 - 51
  • [40] A phase I study of a fixed dose of cisplatin with increasing doses of raltitrexed (Tomudex®) in the treatment of patients with locally advanced or metastatic squamous cell carcinoma of the head and neck
    Huinink, DT
    Tesselaar, MET
    de Jong, RBB
    Verschuur, HP
    Keizer, HJ
    ANNALS OF ONCOLOGY, 2001, 12 (03) : 357 - 363
12345